Self-administered intranasal etripamil using a symptom-prompted, repeat-dose regimen for atrioventricular-nodal-dependent supraventricular tachycardia (RAPID): a multicentre, randomised trial

Bruce S. Stambler(Fundacion Allende), Denise Sorrentino, Ramin Manshadi, A. John Camm(St George's, University of London), Gaurang Gandhi, Padraig Gearoid O’Neill, J. Marcus Wharton(Medical University of South Carolina), Hein Heidbüchel(University of Antwerp), Sean Mazer, Jonathan P. Piccini(Clinical Research Institute), Ralph Augostini, Sandeep Talwar, Suneet Mittal(Valley Health System), Richard Kuk, James E. Ip(Cornell University), Silvia Shardonofsky(Vertex Pharmaceuticals (Canada)), Marco Alings(Utrecht University), Atul Verma(McGill University Health Centre), David E. Schleinkofer, Robert E. Goldstein, Robert M. Kinn, Blandine Mondésert(Montreal Heart Institute), Kenneth A. Ellenbogen(Virginia Commonwealth University), Amir Abdel-Wahab, Srivani R. Ambati, Jaco H. Houtgraaf(Diakonessenhuis hospital), Alonzo Jones, Isaac Dor(University of Toronto), Marcos Daccarett, Francis Plat, José Luís Merino(Hospital Universitario La Paz), Paul Dorian(St. Michael's Hospital), Philip T. Sager(United States Nuclear Regulatory Commission), Aditya Verma(University of Toronto), Michael Chen, Karine Roy, Alexandru A Stoian, Michael Koren(Harvard University Press), J. Vijay Jayachandran, Wilson Lam(Princess Margaret Cancer Centre), Stephen L. Winters, Timothy Phelan, David B. Bharucha(Lundbeck (Denmark)), Sean C. Beinart, Peter R. Kowey(Lankenau Institute for Medical Research), T. P. Connelly, Sean D. Pokorney(Duke University)
The Lancet
June 16, 2023
Cited by 38


Related Papers